← All trials
NCT04550832
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2021
- Primary completion
- May 30, 2022
- Completion date
- Jan 30, 2023
- First posted
- Sep 16, 2020
- Last posted
- Nov 8, 2021
- Enrollment
- 75
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- LegoChem Biosciences, IncLead sponsor
- University of California, San FranciscoCollaborator
- Radboud UniversityCollaborator
- Ludwig Maximilians UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.